ArticleInternational journal of chronic obstructive pulmonary disease2020

Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry.

Franck F Rahaghi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.